SLC15A4: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: SLC15A4

NCBI ID: G121260

SLC15A4

SLC15A4: A Potential Drug Target and Biomarker for the Treatment of Cancer

SLC15A4 is a protein that is expressed in various tissues and cells in the human body. It is a member of the selective transport protein family 15 (SLC15), which is known for its ability to transport a wide variety of molecules across cell membranes. One of the unique features of SLC15A4 is its expression in cancer cells, which has led to its potential as a drug target or biomarker for cancer treatment. In this article, we will explore the biology of SLC15A4 and its potential as a drug target for cancer.

Structure and Function

SLC15A4 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and kidney. It is primarily expressed in cancer cells and has been shown to be overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. SLC15A4 is a member of the SLC15 family, which includes several other proteins that are involved in the transport of various molecules across cell membranes. The SLC15 family is characterized by the presence of a transmembrane region and an intracellular loop.

SLC15A4 functions as a protein transporter that is involved in the transport of various molecules across cell membranes. It is specifically designed to transport the amino acid Asp-Glu-Arg (AGR) across cell membranes, which is a key component of the proteinuria that is observed in many types of cancer. In cancer cells, SLC15A4 is often overexpressed, which can lead to the accumulation of AGR in the cell and the development of various types of cancer.

Drug Target Potential

SLC15A4 has been identified as a potential drug target for cancer treatment due to its involvement in the transport of AGR across cell membranes. Many studies have shown that inhibiting the function of SLC15A4 can lead to the inhibition of AGR transport and the reduced formation of proteinuria, which is a hallmark of cancer. This suggests that SLC15A4 may be an effective target for cancer treatment.

One of the potential advantages of targeting SLC15A4 is its effects on multiple types of cancer. While SLC15A4 is often overexpressed in cancer cells, it is also expressed in normal tissues and has been shown to play a role in the regulation of various physiological processes in the body. This suggests that targeting SLC15A4 may have a minimal impact on normal tissue function, making it a potential advantage in cancer treatment.

Biomarker Potential

SLC15A4 has also been identified as a potential biomarker for cancer treatment. The accumulation of AGR in cells that are overexpressing SLC15A4 can be detected using a variety of techniques, such as Western blotting or immunofluorescence. This accumulation of AGR can be used as a marker for the presence of cancer cells in a patient. Additionally, the inhibition of SLC15A4 function has been shown to reduce the formation of proteinuria, which is a hallmark of cancer. This suggests that SLC15A4 may be a useful biomarker for the diagnosis and monitoring of cancer.

Conclusion

SLC15A4 is a protein that has been identified as a potential drug target and biomarker for cancer treatment. Its involvement in the transport of AGR across cell membranes and its potential as a cancer biomarker make it an attractive target for cancer treatment. Further research is needed to fully understand the biology of SLC15A4 and its potential as a drug

Protein Name: Solute Carrier Family 15 Member 4

Functions: Proton-coupled amino-acid transporter that mediates the transmembrane transport of L-histidine and some di- and tripeptides from inside the lysosome to the cytosol, and plays a key role in innate immune response (PubMed:16289537, PubMed:25238095, PubMed:29224352). Able to transport a variety of di- and tripeptides, including carnosine and some peptidoglycans (PubMed:29224352, PubMed:31073693). Transporter activity is pH-dependent and maximized in the acidic lysosomal environment (By similarity). Involved in the detection of microbial pathogens by toll-like receptors (TLRs) and NOD-like receptors (NLRs), probably by mediating transport of bacterial peptidoglycans across the endolysosomal membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand, and L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptanedioate (tri-DAP), the NOD1 ligand (PubMed:25238095, PubMed:29224352). Required for TLR7, TLR8 and TLR9-mediated type I interferon (IFN-I) productions in plasmacytoid dendritic cells (pDCs) (PubMed:25238095). Independently of its transporter activity, also promotes the recruitment of innate immune adapter TASL to endolysosome downstream of TLR7, TLR8 and TLR9: TASL recruitment leads to the specific recruitment and activation of IRF5 (PubMed:32433612). Required for isotype class switch recombination to IgG2c isotype in response to TLR9 stimulation (By similarity). Required for mast cell secretory-granule homeostasis by limiting mast cell functions and inflammatory responses (By similarity)

The "SLC15A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC15A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets